Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer

被引:0
|
作者
Garcia-Sayre, Jocelyn [1 ,6 ]
Lin, Yvonne G. [1 ]
Matuso, Koji [1 ]
Tsao-Wei, Denice D. [2 ]
Mhawech-Fauceglia, Paulette [3 ]
Louie, Stan [4 ]
Dong, Tiange [4 ]
Ciccone, Marcia A. [1 ]
Brunette-Masi, Laurie L. [1 ]
Pham, Huyen Q. [1 ]
Yessaian, Annie A. [1 ]
Groshen, Susan G. [2 ]
Facio, Grace [1 ]
Aldana, Marissa [1 ]
Muderspach, Laila I. [1 ]
Garcia, Agustin A. [5 ]
Roman, Lynda [1 ]
机构
[1] Univ Southern Calif Los Angeles, Dept Obstet & Gynecol, Div Gynecol Oncol, Los Angeles, CA USA
[2] Univ Southern Calif Los Angeles, Norris Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA USA
[3] LMC Pathol Son Hlth, Las Vegas, NV USA
[4] Univ Southern Los Angeles, Sch Pharm, Los Angeles, CA USA
[5] Louisiana State Univ, Dept Internal Med, Div Hematol Oncol, New Orleans, LA USA
[6] Univ Southern Calif Los Angeles, Dept Obstet & Gynecol, Div Gynecol Oncol, 2020 Zonal Ave,IRD520, Los Angeles, CA 90033 USA
关键词
Cervical cancer; Chemotherapy; Biomarkers; SQUAMOUS-CELL CARCINOMA; HALICHONDRIN B ANALOG; RANDOMIZED-TRIAL; UTERINE CERVIX; OPEN-LABEL; PACLITAXEL; CISPLATIN; ANTHRACYCLINE; MESYLATE; EFFICACY;
D O I
10.1016/j.ygyno.2023.02.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Eribulin a microtubule targeting agent and analog of Halichondrin B, a natural product isolated from marine sponge H. okadai, has proven clinical efficacy in metastatic pretreated breast cancer and liposar-coma. We conducted a 2-stage Phase II study of eribulin in patients with advanced/recurrent cervical cancer to examine its clinical activity and evaluate biomarkers for predictors of response.Methods. Women with advanced/recurrent cervical cancer after <= 1 prior chemotherapy regimen, measurable disease and ECOG performance status <= 2 were treated with eribulin (1.4 mg/m2 IV day 1 and 8, every 21 days) with tumor assessments every 2 cycles. Primary endpoint was 6-month progression-free survival (PFS6); secondary were best overall response (RECISTv1.1), toxicity (CTCAEv4.03) and overall survival (OS). Exploratory endpoints were associations of biomarkers with clinical activity. Immunohistochemistry was performed on archival tumor samples. Overexpression was defined when both intensity and distribution scores were >= 2.Results. 32 patients enrolled from 11/2012-5/2017. 29/32 patients had prior chemotherapy with cisplatin/ paclitaxel/bevacizumab (n = 12) or cisplatin/gemcitabine (n = 12) as the most common regimens. 14 patients received prior paclitaxel. 1 (3%) had a complete response, 5 (16%) had a partial response and 13 (41%) had stable disease for ORR of 19% (95% CI 8, 37). Those who are paclitaxel naive experienced the greatest benefit with a 29% ORR (95% CI 12, 54). Patients who received prior paclitaxel responded less favorably than those who did not (p = .002) and had a shorter PFS and OS. Grade 3/4 adverse events occurring in >10% of patients were anemia (n = 12, 38%), neutropenia (n = 7, 22%) and leukopenia (n = 6, 19%). Analysis of correlative predictors of response re-vealed that patients who did not overexpress SII and BAX were significantly more likely to respond to e`ribulin. PFS was significantly shorter in patients with SII and BAX overexpression, OS was significantly shorter in those with SIII and BAX overexpression. These associations remained after multivariate analysis.Conclusions. Eribulin shows modest activity in patients with recurrent/advanced cervical cancer with a favor-able toxicity profile. Prior paclitaxel exposure is associated with decreased eribulin response. SII, SIII tubulin
引用
收藏
页码:49 / 57
页数:9
相关论文
共 50 条
  • [21] Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
    Xu, Qin
    Chen, Chuanben
    Sun, Yang
    Huang, Zhangzhou
    Lin, Yibin
    Liu, Jing
    Li, Li
    Li, Zirong
    Pan, Junping
    Chen, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Clinical trials for advanced or recurrent cervical cancer
    Kim, Jae-Weon
    Kim, Se Ik
    ANNALS OF ONCOLOGY, 2023, 34 : S1358 - S1358
  • [23] Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies
    Rodriguez, Cristina P.
    Martins, Renato G.
    Baik, Christina
    Chow, Laura Q.
    Santana-Davila, Rafael
    Goulart, Bernardo H.
    Lee, Sylvia
    Eaton, Keith D.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2018, 40 (03): : 584 - 589
  • [24] A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer
    Naoya Murakami
    Shingo Kato
    Takashi Nakano
    Takashi Uno
    Takeharu Yamanaka
    Hideyuki Sakurai
    Ryoichi Yoshimura
    Junichi Hiratsuka
    Yuki Kuroda
    Kotaro Yoshio
    Jun Itami
    BMC Cancer, 16
  • [25] A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer
    Murakami, Naoya
    Kato, Shingo
    Nakano, Takashi
    Uno, Takashi
    Yamanaka, Takeharu
    Sakurai, Hideyuki
    Yoshimura, Ryoichi
    Hiratsuka, Junichi
    Kuroda, Yuki
    Yoshio, Kotaro
    Itami, Jun
    BMC CANCER, 2016, 16
  • [26] Phase II trial of topotecan, cisplatin, and bevacizurnab for recurrent or persistent cervical cancer
    Zighelboim, I.
    Wright, J. D.
    Powell, M. A.
    Case, A. S.
    Eisenhauer, E. L.
    Cohn, D. E.
    Valea, F. A.
    Secord, A. A.
    Lippmann, L. T.
    Rader, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer
    Zighelboim, Israel
    Wright, Jason D.
    Gao, Feng
    Case, Ashley Stephens
    Massad, L. Stewart
    Mutch, David Gardner
    Powell, Matthew A.
    Thaker, Premal H.
    Eisenhauer, Eric Lawernce
    Cohn, David E.
    Valea, Fidel A.
    Secord, Angeles Alvarez
    Lippmann, Lynne T.
    Rader, Janet Sue
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [28] Survival Data From a Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy in Patients With Advanced and Recurrent Cervical Cancer
    Monk, Bradley J.
    Pandite, Lini N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (36) : 4845 - 4845
  • [29] PHASE II TRIAL OF PACLITAXEL, CARBOPLATIN AND BEVACIZUMAB FOR RECURRENT OR PERSISTENT CERVICAL CANCER
    Suzuki, K.
    Nagao, S.
    Kaneda, M.
    Sibutani, T.
    Yamamoto, K.
    Jimi, T.
    Yano, H.
    Kitai, M.
    Shiozaki, T.
    Matsuoka, K.
    Sudo, T.
    Yamaguchi, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 411 - 411
  • [30] Phase II trial of eribulin for recurrent or metastatic salivary gland cancers.
    Eaton, Keith D.
    Goulart, Bernardo H. L.
    Santana-Davila, Rafael
    Chow, Laura Quan Man
    Wood, Rebecca L.
    Rodriguez, Cristina P.
    Baik, Christina S.
    Martins, Renato G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)